Background and Objectives Strategies for overcoming alloimmune refractoriness to random donor platelets are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM). The aim of this study was to review the effectiveness of a platelet XM programme for treating refractory haematological patients at Milan Conclusion This retrospective analysis confirmed the effectiveness of the XM programme at SCB, but revealed defective data collection and retrieval methods at PHM, thus underlining the importance of such methods. The literature review accompanying this retrospective analysis identified a recently described algorithm for ensuring platelet support in refractory patients that optimally integrates the combined use of XM and HLA typing.
Introduction
Platelet transfusion recipients who repeatedly show sub-optimal post-transfusion increases in platelet counts are usually considered 'refractory' to random donor platelets [1, 2] . Refractoriness can be caused by clinical, pharmacological and immunological factors, including alloimmunisation against donor human leucocyte antigens (HLA) and/or (albeit less frequently) human platelet antigens (HPA) [3, 4] . The progressive implementation of the prevalent or universal use of leukoreduced blood components has been followed by a decrease in the frequency of alloimmune refractoriness, which is currently observed in about 1% of platelet transfusion recipients with onco-haematological diseases [5] .
Alloimmunized refractory patients are a significant challenge for blood transfusion services as they are Correspondence: Nicoletta Revelli, DSc, Department of Transfusion Medicine and Hematology, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza, 35, 20122 -Milano, Italy E-mail: nicoletta.revelli@policlinico.mi.it exposed to an increased risk of bleeding in the absence of prompt and effective platelet transfusion. Strategies for overcoming alloimmune refractoriness are based on the use of compatible platelets selected from large panels of HLA-typed donors or cross-matching (XM) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , which have been found to be similarly effective [9] .
In 1999, we introduced the routine use of a platelet XM programme because of the small size of our HLA-typed donor panel and, in 2004, reported satisfactory results in 40 alloimmunized refractory patients [18] . Although our positive results were confirmed by other investigators [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , the findings of studies indicating less satisfactory outcomes [19] prompted us to make this critical retrospective evaluation of the effectiveness of our programme.
Materials and methods

Study setting and organization
This retrospective analysis was based on the patients who received platelet transfusions at the Policlinico Hospital in Milan, Italy (PHM) between December 2002 and December 2014, and those who received platelet transfusions at Spedali Civili in Brescia, Italy (SCB) between February 2013 and December 2016. Both hospitals use a similar platelet XM programme based on a commercially available solid-phase red cell adherence assay (SPRCA).
The hospital medical records of the patients entered in the electronic databases of the platelet XM programmes were retrieved in order to collect general patient data and pre-and post-transfusion platelet counts before the detection of refractoriness and after the activation of the platelet XM programme. The patients' platelet counts were monitored by clinical staff and had to be reported to the blood transfusion services of PHM and SCB.
Refractoriness was defined as two increases in platelet counts (CI) of <5 9 10 9 /L 18-24 h post-transfusion, which usually referred to the platelet counts obtained in the early morning of the day after platelet transfusion. The analysis involved 49 alloimmune refractory patients transfused at PHM and 13 transfused at SCB and was based on the locally available data and documented platelet transfusion outcomes. Out of 49 patients at PMH, 45 (91.8%) had only HLA antibodies and 4 (8Á1%) had HLA with HPA antibodies (1 HPA-1b; 2 HPA-5b and 1 HPA-1b/ HPA-5b). The 13 patients at SCB had only HLA antibodies.
Platelet components and platelet transfusion policy
Adult platelet doses containing a minimum of 2 9 10 11 platelets were prepared using the buffy coat method [20] or by means of apheresis, and stored in 30% plasma and 70% platelet additive solution for a maximum of 5 days at 20-24°C under constant agitation. All of the platelet units were leukoreduced. The random donor platelet concentrates were gamma irradiated at a dose of 30 Gy when clinically indicated, whereas all of the XM platelet units were gamma irradiated.
The buffy coats were prepared by means of the differential centrifugation of 450 mL of whole blood units on the day of donation and stored overnight at 20-24°C. In parallel, an EDTA (at PHM) or CPDA sample (at SCB) was collected from each blood donor and stored for possible future use in the XM procedure. Following the completion of microbiological testing (typically within 18-24 hours of donation), the platelet suspensions were cross-matched with the plasma (at PHM) or serum (at SCB) of the refractory patients. Finally, 4-5 XM-negative buffy coats were pooled and diluted with platelet additive solution in order to be able to prepare and transfuse an adult platelet dose containing at least 2 9 10 11 platelets. Alternatively, an XM compatible platelet apheresis unit was transfused. Each XM session included the testing of a mean of 70 donors (range 12-40) up to a maximum of 94 depending on availability. In a small number of cases, when the first plate yielded no negative donors, an additional plate was tested. With the above strategy, there were no XM sessions yielding no compatible donors.
Both PHM and SCB adopted a prophylactic transfusion strategy, with a pretransfusion threshold platelet count of 10 9 10 9 /L in stable patients, and 20 9 10 9 /L in patients with documented sepsis, rapidly declining platelet counts, and a body temperature of ≥38°C.
Platelet-reactive antibody detection and XM procedures
Platelet-reactive antibodies were screened using a Capture P Ready Screen kit (CPRS) on Galileo or NeoGalileo instruments (Immucor, Norcross, GA). A CPRS kit consists of 13 platelets immobilised in individual wells, typed for HPA-1, 3, 4 and 5, and most HLA antigens. Patients with a positive antibody test were subsequently tested with PAK-Plus or PAK 12 kits (Immucor), which can distinguish anti-HPA from anti-HLA class I antibodies. The patients with positive screening results and anti-HLA class I antibodies entered the XM programme. Serological XM was carried out using Capture P plates (Immucor) on Galileo or NeoGalileo instruments. All of the procedures were carried out following the manufacturer's instructions. No significant technological and operational changes occurred during the study intervals at PHM (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) and at SCB (2013-2016).
Statistical analysis
Descriptive statistics are reported as percentages or median values and interquartile ranges (IQR). Table 1 shows the number of adult platelet doses prepared at PHM and SCB, and the number of recipients of platelet transfusion during the study periods. About onethird of all of the platelet recipients at both hospitals had a haematological diagnosis and received about two-thirds of the available platelet units.
Results
The results of the platelet-reactive antibody screenings and the number of patients included in the retrospective analysis are shown in Table 2 . PHM screened a higher proportion of haematological recipients than SCB: all of the patients identified as refractory and alloimmunized at SCB were transfused locally, whereas 40% of those identified at PHM were transfused at different hospitals. The transfusion outcomes of about two-thirds of the internally transfused refractory patients were available for the analysis (59% at PHM and 72% at SCB). The patients enrolled at PHM were slightly older (median age 67 vs. 57 years) and were more frequently male (24/49 vs. 3/13). Table 3 shows the conditions and medical treatment of the enrolled alloimmunized refractory patients. The most frequent diagnosis at both hospitals was acute myeloid leukaemia (84% of the patients at SCB). Table 4 shows the number of platelet transfusions analysed before and after the detection of alloimmune refractoriness. The XM programme allowed the provision of a median of 12 and 18 compatible platelets per patient at PHM and SCB, respectively. A difference in the effectiveness of the XM programme at the two hospitals is suggested by the fact that 276 random platelets were transfused after the detection of refractoriness at PHM as against none at SCB. Tables 5 and 6 , respectively, show the post-transfusion increases in platelet counts at both hospitals, and the proportion of transfusions leading to a post-transfusion increase of <5 9 10 9 /L after 18-24 h at PHM.
Discussion
This article describes the findings of a critical review of the platelet XM programmes implemented by two Italian hospitals using a commercially available solid-phase antibody assay to select compatible platelets for haematological patients with alloimmune refractoriness to random donor platelets. The study was triggered by a recent investigation reporting the very limited efficacy of platelet XM and HLA selection [19] , which conflicted with the findings of a number of positive studies, including one previously published by our group [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In 2004, we evaluated the increases in platelet counts after 569 XM compatible platelet transfusions administered to 40 alloimmune refractory patients (8.3% of 480 haematological patients transfused before the routine implementation of platelet leukoreduction) [18] . All of the platelet units transfused in that study were prepared using the buffy coat method, and the mean pretransfusion, 1 h post-transfusion and 24 h post-transfusion platelet counts were, respectively, 7Á7, 32Á0 and 16Á8 9 10 9 /L. The posttransfusion increases in platelet counts after the transfusion of XM compatible platelets were significantly higher than those recorded in the same patients when they received random platelets and the corresponding counts were, respectively, 7Á0, 15Á9 and 9Á6 9 10 9 /L.
Other investigators subsequently reported the positive outcomes of other platelet XM programmes. In 2011, Sayed et al. [16] reported good responses to 57Á7% of the transfusions of single-donor apheresis platelets selected using flow cytometry XM, as against 12Á5% of the transfusions of random platelets. Wiita and Nabiar [15] showed that refractory patients could be supported by SPRCA-XM compatible platelets for several weeks or even months of intensive transfusion therapy in a study of 66 refractory patients who received 738 XM compatible single-donor platelets between 2002 and 2010: the mean 1-hour corrected CI (CCI, defined as the CI multiplied by the patient's body surface area and divided by the platelet dose) was 7000 when using XM compatible platelets and 710 when using random platelets.
A study published in 2014 by Elhence et al. [13] used a modified antigen capture enzyme-linked immunosorbent assay to select compatible single-donor platelets, which led to a significantly higher mean 24-h CCI (9250) than the use of incompatible platelets (6757). In the same year, mean 1 h post-transfusion CCIs of, respectively, 8700 and 3600 were reported by Jia et al. [11] after the transfusion of 88 XM compatible and 43 random single-donor apheresis platelet transfusions in 56 patients. More recently, Wang et al. [8] have reported a mean 24-h CCI of 7800 after the administration of 480 XM compatible platelet transfusions to 82 recipients, a value that is statistically significantly higher than the 1500 CCI recorded when the same patients had been administered random single-donor apheresis platelets.
However, the above findings were not supported by Rioux-Mass e et al. [19] , who analysed post-transfusion increases in 32 refractory patients receiving 354 platelet transfusions selected using SPRCA-XM or an HLA-typed donor panel over a period of 3 years: the median 1-4 h CCI was 1Á7 9 10 9 /L using XM compatible platelets and 1Á2 9 10 9 /L using HLA-typed platelets. The authors also reported that 'only 25 and 30% of the XM compatible or HLA-selected units, respectively, gave 1-to 4-h CCIs of more than 5000 compared to 12.5% of the transfusions from random donors', a statistically nonsignificant difference, and concluded that 'clinical factors may overpower immunological matching'. Our critical review of the platelet XM programmes used at PHM and SCB has provided some valuable data that will contribute to improving our ability to support patients' refractory to random donor platelet support. First of all, it was disappointing to note that the patients' medical records at PHM often lacked information concerning pre-and post-transfusion platelet counts: as shown in Table 5 , a record of 1-h and 18-24 h posttransfusion increases in platelet counts was available for only about 7% (52/794) and 37% (295/794) of the transfusions, respectively. This clearly prevented us from drawing any accurate conclusions concerning the lack of effectiveness of the current XM programme at PHM, although the very low median CI of 2 9 10 9 /L 18-24 h post-transfusion reported after 37% of the transfusions clearly contrasts with findings of our 2004 study and suggests that patient and data selection bias may have had an impact on our current findings. In this regard, it is possible that some PHM clinicians may have paid more attention and ordered post-transfusion platelet counts increments more frequently in the less responsive patients. On the contrary, records of 1 h post-transfusion CIs were available for virtually all of the transfusions administered at SCB (47/47 with random platelets and 325/326 with XM compatible platelets), thus indicating the hospital's efficient organization of data management and retrieval, and allowing us to be fully confident that there was a real improvement in the median 1-h CI (3 9 10 9 /L with random platelets and 10 9 10 9 /L with XM compatible platelets). The different outcomes obtained at the two hospitals reinforces the view that effective programmes for the management of patients who are refractory to platelet transfusions require close coordination between the teams treating the patients and the blood transfusion service [7] . We are therefore planning to improve the connection between the blood transfusion and clinical laboratory data management systems at PHM in order to ensure that the patients' complete blood counts are automatically included in each request for a platelet transfusion and avoid mistakes and incompleteness due to passive reporting.
The data shown in Table 2 indicate some other interesting differences between the XM programmes in PHM and SCB. It can be seen that the percentage of patients screened for the presence of platelet-reactive antibodies was much higher at PHM (34% vs. 4%), possibly because of other practical and organizational issues. It is not particularly surprising that the more conservative screening policy at SCB was accompanied by a higher positivity rate (40% vs. 18%), but the high negativity rates at both hospitals (60% and 82%) suggest that the indication for the antibody screening of refractory patients should be refined, particularly at PHM and in the case of patients whose refractoriness is probably due to detrimental clinical or pharmacological factors. This is even more important at a time when there is a need to make optimal use of the available resources.
Comparison of the two programmes also revealed that, after the detection of refractoriness, no random platelets were administered at SCB, whereas 276 random units (25.8% of 1070 platelet units) were transfused at PHM because of a lack of XM compatible units. We discussed this finding with the clinicians and found that they may be induced to request 'any' platelets for refractory thrombocytopenic recipients as a result of legal concerns and/or for purposes of defensive medicine.
The retrospective nature of our analysis provided an opportunity to discuss the proposal to integrate XM and HLA typing when treating alloimmune refractory patients made by Juskewitch et al., [7] who have 'developed a diagnostic and management algorithm [. . .] with an early focus on identifying those cases caused by immunemediated factors. Using physical platelet cross-matches to initially classify platelet transfusion-refractory patients as immune-mediated or not, cross-match-compatible inventory is then provided to immune-mediated patients, whereas subsequent HLA (with or without HPA) testing is performed'. Rather than only using a physical platelet XM programme as an alternative to selecting compatible platelets from an HLA-typed donor panel, the authors state that their integrated model 'leads to overall resource savings and improved clinical management for platelet transfusion-refractory patients'. On the basis of this positive experience, we plan to improve our programmes by giving more consideration to patients' transfusion history and clinical condition.
Finally, we agree with the comments of the authors of a recent systematic review of the usefulness of XM platelet transfusions in patients who are refractory to random donor support [14] . Although they showed that XM platelets increase platelet counts in refractory patients, they also pointed out the lack of data concerning the impact of XM compatible platelets on haemorrhaging and mortality.
